Pancytopenia News and Research

RSS

Clinical dilemmas in breast cancer patients solved by newly approved PET imaging agent

A non-invasive, patient-friendly imaging technique can help physicians make treatment decisions for breast cancer patients when diagnostic dilemmas arise.

29 Sep 2021

Brazilian researchers identify new species of parasite in fatal case of visceral leishmaniasis

Brazilian researchers believe they have identified in patients treated at the University Hospital (HU) in Aracaju, state of Sergipe, a new species of parasite that can cause a disease similar to visceral leishmaniasis but is resistant to the treatments currently available.

1 Oct 2019

FDA approves expanded use of systemic therapy for treating chronic moderate-to-severe pediatric psoriasis

Amgen today announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for the expanded use of ENBREL (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis.

7 Nov 2016

Positive bosutinib response for elderly blast phase CML patient

A case study suggests that the third-generation tyrosine kinase inhibitor bosutinib may be considered as induction therapy for blast phase chronic myeloid leukaemia in older patients.

22 Jan 2016

Bayer to present new research findings on Xofigo (radium Ra 223 dichloride) injection at ASCO GU 2016

Bayer announced today that new research findings on Xofigo (radium Ra 223 dichloride) injection will be presented at the 2016 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU) taking place January 7 – 9 in San Francisco.

4 Jan 2016

Turing Pharmaceuticals acquires rights to market Daraprim (pyrimethamine) in the U.S.

Turing Pharmaceuticals AG today announced that it has acquired the exclusive rights to market Daraprim (pyrimethamine) in the U.S. from Impax Laboratories, Inc. The acquisition by Turing is part of a strategic effort focused on treatments for toxoplasmosis and other serious infectious diseases. The company also announced plans to invest in the development of new drug candidates for toxoplasmosis.

10 Aug 2015

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD (Merck & Co., Inc., Kenilworth, New Jersey, USA) today announced that on 22 June the European Commission approved SIMPONI (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA).

26 Jun 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is sponsoring several data presentations on Cimzia (certolizumab pegol) at Digestive Disease Week 2015, taking place in Washington, DC from May 16-19.

17 May 2015

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology.

3 Jul 2014

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announced today results from the PRECiSE 3 7-year open label extension clinical trial of Cimzia (certolizumab pegol), the longest continuous trial of an anti-TNF therapy evaluating long-term safety in Crohn's disease.

6 May 2014

Edison Pharmaceuticals begins EPI-743 clinical trial in children with Pearson syndrome

Edison Pharmaceuticals today announced the initiation of a phase 2 study entitled "A Phase 2 Safety and Efficacy Study of EPI-743 (Vincerinone™) in Children with Pearson Syndrome." The Investigative New Drug application (IND) was approved by the Food and Drug Administration, Office of Hematology and Oncology Products.

17 Mar 2014

European Commission grants marketing authorization for Bayer HealthCare's Xofigo injection

Bayer HealthCare announced today that the European Commission has granted marketing authorization for Xofigo (radium Ra 223 dichloride) solution for injection for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. This decision follows a positive recommendation from the European Committee for Medicinal Products for Human Use in September of this year.

15 Nov 2013

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis.

18 Oct 2013

New research identifies protein that controls formation of different types of mature blood cells

New research in the Journal of Experimental Medicine identifies a protein that controls the formation of different types of mature blood cells - a finding that could be important to developing new treatments for blood diseases and helping realize the potential of regenerative medicine.

8 Oct 2013

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis.

30 Sep 2013

CHMP recommends approval of Xofigo for CRPC, symptomatic bone and visceral metastases

Bayer HealthCare announced today that the the European Committee for Medicinal Products for Human Use recommended Xofigo (radium Ra 223 dichloride) for approval with a proposed indication for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.

20 Sep 2013

ARIAD Pharmaceuticals' Iclusig gets EC marketing authorization for CML and Ph+ ALL treatment

ARIAD Pharmaceuticals, Inc. today announced that the European Commission has granted a marketing authorization for Iclusig (ponatinib) as an orphan medicinal product for two indications.

2 Jul 2013

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar (sorafenib) tablets, Stivarga (regorafenib) tablets and the recently U.S. Food and Drug Administration approved product Xofigo (radium Ra 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology, May 31 – June 4, in Chicago, IL (USA).

16 May 2013

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).

20 Feb 2013

CNIO team generates transgenic mouse model for aplastic anaemia associated with short telomeres

Aplastic anaemia is characterised by a reduction in the number of the bone marrow cells that go on to form the different cell types present in blood (essentially red blood cells, white blood cells and platelets). In most cases, the causes of the disorder are hard to determine, but some patients have been found to have genetic alterations leading to a shortening of their telomeres (the end regions of chromosomes that protect and stabilise DNA).

30 Aug 2012